Form 4: Rocket Pharmaceuticals Executive Acquires Shares and Options

Kinnari Patel, a Rocket Pharmaceuticals executive, acquired shares and options in the company, as reported in a recent SEC filing.

Summary

• On February 11, 2025, Kinnari Patel, President, Head of R&D and Chief Operating Officer of Rocket Pharmaceuticals, acquired 57,786 shares of common stock.
• These shares were acquired at a price of $0.
• Patel also acquired options to purchase 172,214 shares of common stock at an exercise price of $9.88.
• One-third of the options will vest on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years.
• Following these transactions, Patel directly owns 450,181 shares of common stock and 172,214 stock options.
• Patel also indirectly owns 5,675 shares through her spouse and 104,927 shares through Adaptive Technology LLC, a limited liability company owned and managed by her husband.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard transaction of stock and option awards to an executive. It doesn't inherently indicate positive or negative performance for the company.

Future Outlook

The acquired stock options will vest over a three-year period, contingent on the reporting person's continued employment with the Issuer.

Industry Context

This filing reflects routine transactions by company insiders and is a common occurrence in publicly traded companies. It provides transparency into the holdings of key personnel and their alignment with shareholder interests.

Stakeholder Impact

• The transaction increases the executive's stake in the company, aligning her interests with those of shareholders.

Key Dates